A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs). The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle. The complexes formed by CDK4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase. CDK4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen and a protein, p21 (refs 7-9). CDK4 associates separately with a protein of M(r) 16K, particularly in cells lacking a functional retinoblastoma protein. Here we report the isolation of a human p16 complementary DNA and demonstrate that p16 binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. p16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p16, on the other hand, acts through the Retinoblastoma (Rb) pathway (Serrano et al, 1993).”
From Distinct senotypes in p16- and p21-positive cells across human and mouse aging tissues (2025) · cites this paper as Serrano et al, 1993
In the citing paper
“p16INK4A is a 16 KDa protein that directly binds to CDK4/6 and blocks the formation of cyclinD-CDK4/6 complexes, thereby preventing phosphorylation of RB and promoting expression of E2F target genes (Serrano et al., 1993).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Serrano et al., 1993
In the citing paper
“This member of the INK4a family is a cyclin D-dependent kinase CDK4 and CDK6 inhibitor, which prevents the phosphorylation of the retinoblastoma protein (Rb), therefore leading to suspension of the cell cycle before the S-phase [78,79].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [78]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
A novel genetic system to detect protein–protein interactions
Fields, S., & Song, O.-K. (1989) · Nature · doi:10.1038/340245a0 · Cited by 6,114
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Self-citationSherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
Self-citationFunctional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
A family of human cdc2-related protein kinases.
Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., Harlow, E., & Tsai, L. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 923
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Research works printed but not linked: 2
- Motokura, T. & Arnold, A. Biochim. biophys. Acta 1155, 63–78 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene (in the press).
Cited by
Items 401–500 of 1,022
Arendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 188
Frequent Hypermethylation of p16 and p15 Genes in Multiple Myeloma
Ng, M. H. L., Chung, Y. F., Lo, K. W., Wickham, N. W. R., Lee, J. C. K., & Huang, D. P. (1997) · Blood · doi:10.1182/blood.v89.7.2500 · Cited by 187
CDKN2A Germline Mutations in Familial Pancreatic Cancer
Bartsch, D. K., Sina-Frey, M., Lang, S., Wild, A., Gerdes, B., Barth, P., Kress, R., Grützmann, R., Colombo-Benkmann, M., Ziegler, A., et al. (2002) · Annals of Surgery · doi:10.1097/00000658-200212000-00005 · Cited by 186
“p16 produces a G1 cell-cycle arrest by inhibiting phosphorylation of the retinoblastoma protein, and p14 acts both at G1/S and G2/M phases in a p53-dependent manner via binding and inhibition of the protein MDM2.(16,17) p16 is inactivated in 95% of sporadic pancreatic cancers,(18) indicating its important role in the…”
BackgroundHypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
Klump, B., Hsieh, C.-J., Holzmann, K., Gregor, M., & Porschen, R. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70016-2 · Cited by 186
Lu, S., Liu, M., Epner, D. E., Tsai, M., & Tsai, M. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.376 · Cited by 185
“The first class of CDK inhibitors comprises p16 (also called MTS1, INK4a) (2), p15 (also called MTS2, INK4b) (3), p18 (4), and p19 (5).”
BackgroundP16INK4A—More Than a Senescence Marker
Safwan-Zaiter, H., Wagner, N., & Wagner, K.-D. (2022) · Life · doi:10.3390/life12091332 · Cited by 181
“When the cell passes the restriction point, cyclin E-Cdk2 hyperphosphorylates pRB, which dissociates from the E2F factors, which in turn translocate to the nucleus and activate transcription of S phase genes [3,33,58,62].”
BackgroundSteinman, R., Hoffman, B., Liebermann, D. A., & Fisher, P. B. (1995) · Science · doi:10.1126/science.7716532 · Cited by 183
Elenitoba-Johnson, K. S. J., Gascoyne, R. D., Lim, M. S., Chhanabai, M., Jaffe, E. S., & Raffeld, M. (1998) · Blood · doi:10.1182/blood.v91.12.4677 · Cited by 179
Methylation Silencing and Mutations of the p14ARF and p16INK4a Genes in Colon Cancer
Burri, N., Shaw, P., Bouzourene, H., Sordat, I., Sordat, B., Gillet, M., Schorderet, D., Bosman, F. T., & Chaubert, P. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780230 · Cited by 181
“…at 9p21, contains two tumor suppressor genes, p16INK4a (CDKN2A, MTS1) and p14ARF (p19ARF in the mouse), characterized by two distinct promoters and first exons spliced to a common exon 2 in different reading frames (Mao et al, 1995; Quelle et al, 1995; Serrano et al, 1993; Stone et al, 1995).”
BackgroundBian, Y., Osterheld, M., Fontolliet, C., Bosman, F. T., & Benhattar, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32370 · Cited by 182
Biliran, H., Wang, Y., Banerjee, S., Xu, H., Heng, H., Thakur, A., Bollig, A., Sarkar, F. H., & Liao, J. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2419 · Cited by 181
Small Molecules as Inhibitors of Cyclin‐Dependent Kinases
Huwe, A., Mazitschek, R., & Giannis, A. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200540 · Cited by 181
Brown, V. L., Harwood, C. A., Crook, T., Cronin, J. G., Kelsell, D. P., & Proby, C. M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22501.x · Cited by 179
p16Ink4a in Melanocyte Senescence and Differentiation
Sviderskaya, E. V. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.6.446 · Cited by 179
Molecular Genetics and Epidemiology of Prostate Carcinoma
Ruijter, E., van de Kaa, C., Miller, G., Ruiter, D., Debruyne, F., & Schalken, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.1.0356 · Cited by 179
“Methylation analysisofaCpG-richpromotorregioninexon1ofthe CDKN2generevealeddensemethylationinthreePCacell lines(TSU-PR1,PPC-1,PC-3),andthiswasfoundtocorrelate withalackofmRNAexpressionbyRT-PCR(32).”
BackgroundInfluentialHigh frequency of p16INK4A gene alterations in hepatocellular carcinoma
Liew, C. T., Li, H.-M., Lo, K.-W., Leow, C. K., Chan, J. Y., Hin, L. Y., Lau, W. Y., Lai, P. B. S., Lim, B. K., Huang, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202359 · Cited by 180
“The p16 gene is believed to encode a negative regulatory protein which prevents the cell cycle progression from G1 to S phase by inhibiting the catalytic activity of the CDK4 or CDK6/cyclin D complex and subsequently Rb protein phosphorylation (Serrano et al., 1993; Kamb et al., 1994).”
BackgroundIdentification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1.
Nakanishi, M., Robetorye, R. S., Adami, G. R., Pereira-Smith, O. M., & Smith, J. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07031.x · Cited by 178
Robles, A. I., Larcher, F., Whalin, R. B., Murillas, R., Richie, E., Gimenez-Conti, I. B., Jorcano, J. L., & Conti, C. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7634 · Cited by 177
Jimenez, G. S., Khan, S. H., Stommel, J. M., & Wahl, G. M. (1999) · Oncogene · doi:10.1038/sj.onc.1203013 · Cited by 177
“…entry by inhibiting the phosphorylation of pRb which promotes the sequestration of the E2F family of transcription factors (Chellappan et al., 1991; Serrano et al., 1993). p19ARF may also promote G1 arrest in the presence of microtubule antagonists by interfering with the MDM2-mediated degradation…”
BackgroundControl of p53 ubiquitination and nuclear export by MDM2 and ARF.
Zhang, Y., & Xiong, Y. (2001) · PubMed · Cited by 213
The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo
Yang, Z.-Y., Perkins, N. D., Ohno, T., Nabel, E. G., & Nabel, G. J. (1995) · Nature Medicine · doi:10.1038/nm1095-1052 · Cited by 178
Expression of cell cycle-associated proteins in human and rabbit corneal endothelium in situ.
Joyce, N. C., Navon, S. E., Roy, S., & Zieske, J. D. (1996) · PubMed · Cited by 194
Bettendorf, O., Piffkò, J., & Bànkfalvi, A. (2004) · Oral Oncology · doi:10.1016/j.oraloncology.2003.08.010 · Cited by 176
Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins
Beijersbergen, R. L., & Bernards, R. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(96)00002-9 · Cited by 176
Lu, S., Tsai, S. Y., & Tsai, M. (1997) · PubMed · Cited by 191
Andreasson, P., Johansson, B., Arheden, K., Billström, R., Mitelman, F., & Höglund, M. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199706)19:2<77::aid-gcc2>3.0.co;2-x · Cited by 42
Myc oncogenes: the enigmatic family
RYAN, K. M., & BIRNIE, G. D. (1996) · Biochemical Journal · doi:10.1042/bj3140713 · Cited by 175
Kaneko, Y., Yoshida, K., Handa, M., Toyoda, Y., Nishihira, H., Tanaka, Y., Sasaki, Y., Ishida, S., Higashino, F., & Fujinaga, K. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199602)15:2<115::aid-gcc6>3.0.co;2-6 · Cited by 239
Parry, D., Mahony, D., Wills, K., & Lees, E. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1775 · Cited by 174
“Association of the D-type cyclins with CDK4 and CDK6 is also influenced by the INK4 family of CDK inhibitors (p15, p16, p18, and p19) (9, 10, 12, 18, 42).”
BackgroundCellular senescence in the aging and diseased kidney
Valentijn, F. A., Falke, L. L., Nguyen, T. Q., & Goldschmeding, R. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0434-2 · Cited by 173
“…causes Rb to remain attached to and thereby inhibit the transcriptionally active E2F protein complex, thus preventing G1/S transition and DNA replication, or G2/M progression and mitosis, ultimately limiting cellular proliferation (Zhang et al. 1993; Serrano et al. 1993; Jullien et al. 2013) (Fig.”
BackgroundmTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas
Molinolo, A. A., Marsh, C., El Dinali, M., Gangane, N., Jennison, K., Hewitt, S., Patel, V., Seiwert, T. Y., & Gutkind, J. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2824 · Cited by 173
“This protein is encoded by the CDKN2A (MTS1, INK4A) tumor suppressor gene, and inactivates the function of cdk4- and cdk6-cyclin D complexes, thereby regulating cell proliferation by preventing the inactivation of the retinoblastoma tumor suppressor protein (pRb) by hyperphosphorylation (33).”
BackgroundMelanocortin-1 Receptor Variant R151C Modifies Melanoma Risk in Dutch Families with Melanoma
van der Velden, P. A., Sandkuijl, L. A., Bergman, W., Pavel, S., van Mourik, L., Frants, R. R., & Gruis, N. A. (2001) · The American Journal of Human Genetics · doi:10.1086/323411 · Cited by 173
“[MIM 603368]) (Serrano et al. 1993).”
BackgroundInfluentialCyclins and Cyclin-Dependent Kinases: Theme and Variations
(1995) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60254-7 · Cited by 172
(−)-Epigallocatechin gallate causes oxidative damage to isolated and cellular DNA
Furukawa, A., Oikawa, S., Murata, M., Hiraku, Y., & Kawanishi, S. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00541-0 · Cited by 172
Poon, R. Y. C., Jiang, W., Toyoshima, H., & Hunter, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.13283 · Cited by 172
WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome
Da Forno, P. D., Pringle, J. H., Hutchinson, P., Osborn, J., Huang, Q., Potter, L., Hancox, R. A., Fletcher, A., & Saldanha, G. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5104 · Cited by 170
Glioblastoma multiforme: a review of therapeutic targets
Kanu, O. O., Mehta, A., Di, C., Lin, N., Bortoff, K., Bigner, D. D., Yan, H., & Adamson, D. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942348 · Cited by 171
“As alluded to, p16INK4a is an inhibitor of CDK4, blocks CDK4-dependent phosphorylation of the RB1 protein [136] and acts as a negative regulator of cell proliferation.”
BackgroundNiu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
“The p16 protein directly inhibits the activities of the cyclin D-dependent kinases, cyclin-dependent kinase (CDK) 4 and CDK6, thus maintaining RB in its dephosphorylated, anti-proliferative state, and leading to cell growth arrest.(121) The tumor-suppressor protein p53 plays a pivotal role in regulating cell growth fo…”
BackgroundFåhraeus, R., Paramio, J. M., Ball, K. L., Laín, S., & Lane, D. P. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00425-6 · Cited by 170
A melanoma-associated germline mutation in exon 1β inactivates p14ARF
Rizos, H., Puig, S., Badenas, C., Malvehy, J., Darmanian, A. P., Jiménez, L., Milà, M., & Kefford, R. F. (2001) · Oncogene · doi:10.1038/sj.onc.1204728 · Cited by 171
“…p16INK4a regulates G1-phase exit by interacting with CDK4 and CDK6 to inhibit the phosphorylation of the retinoblastoma protein (pRb) (Serrano et al., 1993). p14ARF regulates both the p53 and pRb pathways, by binding to and inhibiting the function of the proto-oncogene hdm2 (Honda…”
BackgroundAntisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation
Kondo, S., Tanaka, Y., Kondo, Y., Hitomi, M., Barnett, G. H., Ishizaka, Y., Liu, J., Haqqi, T., Nishiyama, A., Villeponteau, B., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.10.801 · Cited by 170
“hibitors of the CDK4/CDK6 kinases (60, 61).”
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
Stewart, Z. A., Leach, S. D., & Pietenpol, J. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.205 · Cited by 168
“There are four known INK4 family members, p16 (48), p15 (13, 24), p19 (21), and p18 (21), and three known Cip/Kip family members, p21 (10, 60), p27 (44, 45, 53), and p57 (28, 31).”
Amplification and overexpression of E2F3 in human bladder cancer
Feber, A., Clark, J., Goodwin, G., Dodson, A. R., Smith, P. H., Fletcher, A., Edwards, S., Flohr, P., Falconer, A., Roe, T., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207274 · Cited by 169
“INK4A/ARF encodes both p14ARF (p19ARF in mouse), which interacts with E2F3, promoting its degradation (Martelli et al., 2001), and p16, which represses the activity of CDK4 (Serrano et al., 1993). p14ARF can also block CDK4 activity through the MDM2/p53/p21 pathway.”
BackgroundAlzheimer's disease as a disorder of mechanisms underlying structural brain self-organization
Arendt, T. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00516-9 · Cited by 169
“106,381 p16 apparently inhibits cdk4 by binding in competition with cyclin D.(682) Malignant cellular transformation has been shown to produce major changes in the modulation of the cyclin-cdk complexes by associated cdkiproteins such as p16.”
BackgroundKourea, H. P., Orlow, I., Scheithauer, B. W., Cordon-Cardo, C., & Woodruff, J. M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65504-6 · Cited by 170
Brain tumours: classification and genes
Collins, V. P. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.040337 · Cited by 169
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Sobhani, N., D’Angelo, A., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., & Otto, T. (2019) · Cells · doi:10.3390/cells8040321 · Cited by 167
“Cyclin-dependent kinase inhibitors include naturally occurring proteins, such as those belonging to the INK4 family—namely p16Ink4a [13], p15Ink4b [14], p18Ink4c [15,16], and p19Ink4d [16,17] (Figure 1).”
BackgroundFrequent Methylation Silencing of p15INK4b(MTS2) and p16INK4a (MTS1) in B-Cell and T-Cell Lymphomas
Baur, A. S., Shaw, P., Burri, N., Delacrétaz, F., Bosman, F. T., & Chaubert, P. (1999) · Blood · doi:10.1182/blood.v94.5.1773 · Cited by 165
Repression of p27 kip1 Synthesis by Platelet-Derived Growth Factor in BALB/c 3T3 Cells
Agrawal, D., Hauser, P., McPherson, F., Dong, F., Garcia, A., & Pledger, W. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4327 · Cited by 168
“proteins thus far characterized, p16, p15, p18, and p19, all have a highly conserved motif consisting of repeated ankyrin motifs (23, 66, 75).”
BackgroundDNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone, G. G. M., Teofili, L., Voso, M. T., & Lübbert, M. (2002) · PubMed · Cited by 200
Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
Biernat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1997) · Acta Neuropathologica · doi:10.1007/s004010050711 · Cited by 166
“The product of the p16 gene binds to CDK4 and CDK6, which prevents their interaction with cyclin D [20, 42 ].”
Backgroundp16 INK4A Participates in a G 1 Arrest Checkpoint in Response to DNA Damage
Shapiro, G. I., Edwards, C. D., Ewen, M. E., & Rollins, B. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.378 · Cited by 165
“p16 is a specific inhibitor of cyclin dependent kinase 4 (cdk4) and cdk6, which participate in the cyclin D-dependent phosphorylation of the retinoblastoma susceptibility gene product, Rb (31).”
BackgroundMethodInfluentialNugroho, T. T., & Mendenhall, M. D. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.5.3320 · Cited by 165
“tween the p40 protein sequence and sequences in the GenBank, EMBL, SwissProt, PIR, and dbest (expressed sequence tags) data bases, sequences in the specialized data base compiled by Mark Goebl (15), or the sequences of other recently isolated Cdk inhibitors (9, 18, 19, 42, 54).”
BackgroundHe, J., Olson, J. J., & James, C. D. (1995) · PubMed · Cited by 188
Molecular pathogenesis of hepatocellular carcinoma
Wong, C., & Ng, I. O. L. (2008) · Liver International · doi:10.1111/j.1478-3231.2007.01637.x · Cited by 165
“Loss of p16 function may limit the tumour suppressor function of the wild-type RB1 gene product and lead to unregulated cellular proliferation (85).”
BackgroundThe role of RB in cell cycle control
Hatakeyama, M., & Weinberg, R. A. (1995) · Progress in Cell Cycle Research · doi:10.1007/978-1-4615-1809-9_2 · Cited by 164
Byeon, I.-J. L., Li, J., Ericson, K., Selby, T. L., Tevelev, A., Kim, H.-J., O'Maille, P., & Tsai, M.-D. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80042-8 · Cited by 163
“While numerous studies have attempted to find by Beach (Serrano et al., 1993) and Skolnick (Kamb et mutations and/or deletions in the gene coding for p19 al.”
InfluentialMurthy, S. S., & Testa, J. R. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199908)180:2<150::aid-jcp2>3.0.co;2-h · Cited by 175
Schwarz, J. K., Bassing, C. H., Kovesdi, I., Datto, M. B., Blazing, M., George, S., Wang, X. F., & Nevins, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.483 · Cited by 164
Ito, Y., Matsuura, N., Sakon, M., Miyoshi, E., Noda, K., Takeda, T., Umeshita, K., Nagano, H., Nakamori, S., Dono, K., et al. (1999) · Hepatology · doi:10.1002/hep.510300114 · Cited by 162
Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
Piepkorn, M. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104687 · Cited by 162
p16 Overexpression Identifies HPV-positive Vulvar Squamous Cell Carcinomas
Santos, M., Landolfi, S., Olivella, A., Lloveras, B., Klaustermeier, J., Suárez, H., Alòs, L., Puig-Tintoré, L. M., Campo, E., & Ordi, J. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213251.82940.bf · Cited by 162
“These complexes regulate the G1 checkpoint by phosphorylation and subsequent inactivation of pRb, which in turn releases E2F allowing the cell to enter in the S phase.(27,30) In all HPV-positive neoplasms, pRb has been shown to be functionally inactivated as a consequence of HPV E7 protein expression,(7) and as a resu…”
BackgroundHomozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias
Ogawa, S., Hirano, N., Sato, N., Takahashi, T., Hangaishi, A., Tanaka, K., Kurokawa, M., Tanaka, T., Mitani, K., & Yazaki, Y. (1994) · Blood · doi:10.1182/blood.v84.8.2431.2431 · Cited by 161
Lingbeek, M. E., Jacobs, J. J. L., & van Lohuizen, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200403200 · Cited by 160
Human ARF binds E2F1 and inhibits its transcriptional activity
Eymin, B., Karayan, L., Séité, P., Brambilla, C., Brambilla, E., Larsen, C.-J., & Gazzéri, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204220 · Cited by 160
“Introduction 3 The INK4a/ARF locus encodes two gene products, p16INK4a and ARF, both of which are crucial for cell growth regulation and senescence (Quelle et al. 1995; Chin et al 1998). p16INK4a is a major component of the RB pathway (Serrano et al 1993).”
BackgroundDai, S., Shan, Z., Nakamura, H., Masuko‐Hongo, K., Kato, T., Nishioka, K., & Yudoh, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21639 · Cited by 160
An, H.-X., Beckmann, M. W., Reifenberger, G., Bender, H. G., & Niederacher, D. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65257-1 · Cited by 160
“Furthermore, it has been hypothesized that alterations of any of the components in the growth-regulatory pathway (p16, pRB, cyclin D1, and CDK4) may have a similar effect leading to disturbance of the cell cycle regulatory system in favor of cell proliferation.(2,30) This hypothesis is supported by the following obser…”
ResultARF Impedes NPM/B23 Shuttling in an Mdm2-Sensitive Tumor Suppressor Pathway
Brady, S. N., Yu, Y., Maggi, L. B., & Weber, J. D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9327-9338.2004 · Cited by 160
“p16 imposes a G1/S phase block via direct inhibition of the cdk4 and cdk6 cyclindependent kinases, maintaining the active, hypophosphorylated state of the retinoblastoma (Rb) tumor suppressor (36).”
BackgroundGizard, F., Amant, C., Barbier, O., Bellosta, S., Robillard, R., Percevault, F., Sevestre, H., Krimpenfort, P., Corsini, A., Rochette, J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22756 · Cited by 160
“Initially, p16 was identified by virtue of its ability to inhibit G1/S cell-cycle progression by binding to CDK4, thus preventing CDK4 association with D-type cyclins and further initiation of pRB phosphorylation by the cyclin D/CDK4 complexes (8, 9, 27).”
BackgroundJin, X., Nguyen, D. M., Zhang, W. W., Kyritsis, A. P., & Roth, J. A. (1995) · PubMed · Cited by 179
Zhou, L., Chen, X., Liu, T., Gong, Y., Chen, S., Pan, G., Cui, W., Luo, Z., Pei, M., Yang, H., et al. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12250 · Cited by 158
“Cell cycle arrest by increased expression of CKI, such as p16, is a hallmark of cellular senescence of MSCs [44].”
BackgroundJarrard, D. F., Sarkar, S., Shi, Y., Yeager, T. R., Magrane, G., Kinoshita, H., Nassif, N., Meisner, L. F., Newton, M. A., Waldman, F. M., et al. (1999) · PubMed · Cited by 187
Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues
Pei, X.-H., & Xiong, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208611 · Cited by 158
“Under most assay conditions, INK4 proteins form binary complexes with either CDK4 or CDK6 and do not detectably interact with cyclin Ds in vivo (e.g. Serrano et al., 1993; Xiong et al., 1993b; Parry et al., 1995), and can in fact dissociate cyclin D–CDK4 complexes in vitro (Ragione et al., 1996).”
BackgroundMethodDirect Vascular Effects of HMG-CoA Reductase Inhibitors
Laufs, U. (2000) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(00)00044-x · Cited by 158
Epigenetic linkage of aging, cancer and nutrition
Daniel, M., & Tollefsbol, T. O. (2015) · Journal of Experimental Biology · doi:10.1242/jeb.107110 · Cited by 157
“…D/CDK4/CDK6 and subsequently releasing the inhibitory retinoblastoma (Rb) gene, resulting in the failure of E2F release and cellular progression (Serrano et al., 1993; Li and Tollefsbol, 2011). p16 was shown to be deleted in ~20% of human breast tumors and epigenetically inactivated in an…”
BackgroundThe Senescence Markers p16INK4A, p14ARF/p19ARF, and p21 in Organ Development and Homeostasis
Wagner, K.-D., & Wagner, N. (2022) · Cells · doi:10.3390/cells11121966 · Cited by 156
Ansari-Lari, M. A., Staebler, A., Zaino, R. J., Shah, K. V., & Ronnett, B. M. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200402000-00002 · Cited by 158
The genetics of pancreatic cancer
Cowgill, S. M., & Muscarella, P. (2003) · The American Journal of Surgery · doi:10.1016/s0002-9610(03)00226-5 · Cited by 180
Huschtscha, L. I., Noble, J. R., Neumann, A. A., Moy, E. L., Barry, P. A., Melki, J. R., Clark, S. J., & Reddel, R. R. (1998) · PubMed · Cited by 186
Cellular Response to Oncogenic Ras Involves Induction of the Cdk4 and Cdk6 Inhibitor p15INK4b
Malumbres, M., Pérez De Castro, I., Hernández, M. I., Jiménez, M., Corral, T., & Pellicer, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2915-2925.2000 · Cited by 153
“p16 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (Cdk4/6) (61), whereas p19 stabilizes the p53 tumor suppressor gene (for reviews, see references 7, 66, and 67).”
BackgroundMolecular genetics of familial cutaneous melanoma.
Haluska, F. G., & Hodi, F. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.670 · Cited by 154
Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
Yoshida, S., Todoroki, T., Ichikawa, Y., Hanai, S., Suzuki, H., Hori, M., Fukao, K., Miwa, M., & Uchida, K. (1995) · PubMed · doi:10.11501/3164579 · Cited by 168
Kaye, F. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205834 · Cited by 153
“…et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which phosphorylates RB in late G1, suggested that the p16 gene could be an important target for mutations in a wide range of…”
BackgroundMolecular Prognostic Markers in Pancreatic Cancer
Coppola, D. (2000) · Cancer Control · doi:10.1177/107327480000700504 · Cited by 153
Platz, A., Hansson, J., Mansson-Brahme, E., Lagerlof, B., Linder, S., Ringborg, U., Lundqvist, E., Sevigny, P., & Inganas, M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.10.697 · Cited by 154
“The CDKN2A gene is located on chromosome 9p21 and encodes a protein, p16INK4A, which acts as an inhibitor of cyclin-dependent kinases 4 and 6 (cdk4 and cdk6) ( 7 ,8).”
BackgroundWesthoff, J. H., Hilgers, K. F., Steinbach, M. P., Hartner, A., Klanke, B., Amann, K., & Melk, A. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.099432 · Cited by 152
The reduced expression and aberrant methylation of p16INK4a in chromate workers with lung cancer
Kondo, K., Takahashi, Y., Hirose, Y., Nagao, T., Tsuyuguchi, M., Hashimoto, M., Ochiai, A., Monden, Y., & Tangoku, A. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.05.022 · Cited by 163
p16INK4a can initiate an autonomous senescence program
Dai, C. Y., & Enders, G. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203438 · Cited by 169
“p16INK4a/MTS1/CDKN2 is an inhibitor of cyclin dependent kinases 4 and 6 and a potent mediator of cell cycle arrest in transient assays (Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995; Serrano et al., 1993, 1995).”
BackgroundCell cycle in mouse development
Ciemerych, M. A., & Siciński, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208608 · Cited by 172
“The INK family encodes inhibitors of cyclin D-CDK4/6 complexes – p16INK4a, p15INK4b, p18INK4c and p19INK4d (Serrano et al., 1993; Hannon and Beach, 1994; Chan et al., 1995; Hirai et al., 1995; Quelle et al., 1995a; Guan et al., 1996).”
BackgroundEvaluation for Safety of Antioxidant Chemopreventive Agents
Kawanishi, S., Oikawa, S., & Murata, M. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1728 · Cited by 152
Genetic Epidemiology of Cutaneous Melanoma: A Global Perspective
Goldstein, A. M., & Tucker, M. A. (2001) · Archives of Dermatology · doi:10.1001/archderm.137.11.1493 · Cited by 183
Overcoming cellular senescence in human cancer pathogenesis
Yeager, T. R., DeVries, S., Jarrard, D. F., Kao, C., Nakada, S. Y., Moon, T. D., Bruskewitz, R., Stadler, W. M., Meisner, L. F., Gilchrist, K. W., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.163 · Cited by 152
Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer
Weinberger, P., Yu, Z., Haffty, B. G., Kowalski, D. P., Harigopal, M., Sasaki, C. T., Rimm, D. L., & Psyrri, A. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0448 · Cited by 151
“The p16 protein exerts a tumor suppressor function by binding to the cyclin D1 CDK4/CDK6 complex preventing phosphorylation of the retinoblastoma (Rb) protein (7).”
BackgroundTien, H., Tang, J., Tsay, W., Liu, M., Lee, F., Wang, C., Chen, Y., & Shen, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02496.x · Cited by 160
“The p15INK4B gene and its functional homologue p16INK4A gene encode protein, negatively regulating the cell cycle by inhibition of cyclin-dependent kinases 4 and 6, which control the progression of cells from G1 to S phase (Serrano et al, 1993).”
BackgroundPromoter-Region Hypermethylation and Gene Silencing in Human Cancer
Herman, J. G., & Baylin, S. B. (2000) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59696-4_3 · Cited by 157
Sesamin, a lignan of sesame, down‐regulates cyclin D1 protein expression in human tumor cells
Yokota, T., Matsuzaki, Y., Koyama, M., Hitomi, T., Kawanaka, M., Enoki‐Konishi, M., Okuyama, Y., Takayasu, J., Nishino, H., Nishikawa, A., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00560.x · Cited by 160
p57KIP2: “Kip”ing the Cell under Control
Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., & Gorgoulis, V. G. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0317 · Cited by 149
“The INK4 family includes p16 (2), p15 (3), p18 (4), and p19 (5, 6).”
Kawesha, A., Ghaneh, P., Andrén‐Sandberg, Å., Ögraed, D., Skar, R., Dawiskiba, S., Evans, J. D., Campbell, F., Lemoine, N. R., & Neoptolemos, J. P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001120)89:6<506::aid-ijc7>3.0.co;2-f · Cited by 152
Metadata
- Authors
- Serrano, M., Hannon, G. J., & Beach, D.
- Affiliations
- Howard Hughes Medical Institute (US)
- ORCID
- Hannon, Gregory J.
- Venue
- Nature
- Published
- 1993-12
- Volume
- 366
- Issue
- 6456
- Pages
- 704-707
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2066848701
- Cited by
- 3,650
- References
- 22
- Citations by year
- 2026: 36 · 2025: 46 · 2024: 52 · 2023: 66 · 2022: 67 · 2021: 78 · 2020: 64 · 2019: 63 · 2018: 56 · 2017: 70 · 2016: 69 · 2015: 75 · 2014: 52 · 2013: 98 · 2012: 88
- FWCI
- 78.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, CDK4, cyclin D, cyclin-dependent kinases, cell cycle regulation, G1 phase, kinase inhibition, retinoblastoma protein, p21, proliferating cell nuclear antigen, feedback regulation, cell proliferation
- MeSH terms
- Amino Acid Sequence, Base Sequence, Carrier Proteins, Cell Cycle, Cloning, Molecular, DNA, Glutathione Transferase, HeLa Cells, Humans, Molecular Sequence Data, Phosphorylation, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Saccharomyces cerevisiae, Oncogene Proteins, Retinoblastoma Protein, Cyclins, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.